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Interleukin (IL)-33 is a recently identified cytokine belonging to the IL-1 family that is widely expressed throughout the body
and has the ability to induce Th2 immune responses. In addition, IL-33 plays a key role in promoting host defenses against
parasites through the expansion of a novel population of innate lymphoid cells. In recent years, a growing body of evidence has
shown that the proinflammatory properties displayed by IL-33 are detrimental in several experimental models of inflammation;
in others, however, IL-33 appears to have protective functions. In 2010, four different research groups consistently described the
upregulation of IL-33 in patients with inflammatory bowel disease (IBD). Animalmodels of IBDwere subsequently utilized in order
to mechanistically determine the precise role of IL-33 in chronic intestinal inflammation, without, however, reaching conclusive
evidence demonstrating whether IL-33 is pathogenic or protective. Indeed, data generated from these studies suggest that IL-33
may possess dichotomous functions, enhancing inflammatory responses on one hand and promoting epithelial integrity on the
other.This review focuses on the available data regarding IL-33/ST2 in the physiological and inflammatory states of the gut in order
to speculate on the possible roles of this novel IL-1 family member in intestinal inflammation.
1. Introduction
The intestinal epithelium is the largest surface area of the
human body in direct contact with the external environment
and exposed to a multitude of foreign microorganisms,
macromolecules, and xenobiotics. As such, a fine regulation
of gut mucosal immune functions is needed to develop
a prompt and self-limiting inflammatory response against
harmful pathogens but also to maintain normal gut home-
ostasis when no potential threat is sensed. Complex interac-
tions between different cell types, effectors of both innate and
adaptive immunity, regulate the inflammatory status within
the intestinal mucosa. Pro- and anti-inflammatory cytokines
represent key players in shaping this network and maintain-
ing the communication among various cell types; balance
among these mediators appears to be critical for gut immune
homeostasis. In fact, a broadwealth of evidence demonstrates
the importance of cytokine dysregulation in the onset of
inflammatory conditions of the gastrointestinal tract. In
particular, IBD, namely, Crohn’s disease (CD) and ulcerative
colitis (UC), is characterized by a significant dysregulation
of cytokine production, with, in general, an overabundance
of proinflammatory mediators [1]. For example, it has been
shown that in the inflamedmucosa of IBD patients and colitis
models, there is a perturbation of the balance between the
proinflammatory cytokine, IL-1, and its naturally occurring
antagonist, the IL-1 receptor antagonist (IL-1Ra), and that
restoring this balance by exogenous administration of IL-1Ra
ameliorates intestinal inflammation [2, 3]. As in the case of
IL-1, othermembers of the IL-1 family, such as IL-18, have also
been implicated in the initiation and perpetuation of chronic
intestinal inflammation [4–6].
The IL-1 family of cytokines is constantly expanding, and,
very recently, newmembers have been identified and studied,
such as IL-1F11, IL-1F6/8/9, IL-1F7, and IL1F10, respectively
known as IL-33, IL-36, IL-37, and IL-38 [7]. To date, of these
novel members, IL-33 is the best characterized in terms of
function and biological effects since its initial description in
2005 [8]. However, controversy still exists as to its precise
role in intestinal disorders, particularly in the development
of IBD. Thus, the aim of this review is to summarize what is
already established regarding the role of IL-33 in the GI tract,
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while providing insight into the potential role of this novel
IL-1 family member in the pathogenesis of chronic intestinal
inflammation.
2. IL-33: A Novel Member of the IL-1 Family
In 2003, a novel 30 kD protein, localized the nuclei of
endothelial cells, was identified and shown to be highly
expressed in high endothelial venules of tonsils, Peyer’s
patches, and lymph nodes [9]. The authors recognized,
within the amino-terminal part of this molecule (aa 1–160),
a novel homeodomain-like Helix-Turn-Helix (HTH) DNA-
binding domain. As such, this protein was hypothesized to
possess nuclear factor function, critical for the induction of a
lymphatic endothelium phenotype, and was therefore coined
“Nuclear Factor-High Endothelial Venules” (NF-HEV) [9].
Two years later, NF-HEV was identified as a novel member
of the IL-1 family, shown to be the ligand for the former
orphaned receptor, ST2, and renamed IL-1F11 or IL-33 [8].
In this first report, IL-33 was described as a potent enhancer
of Th2 responses, inducing the production of IL-5 and IL-13.
IL-33 was reported to be widely expressed in different cell
types and within most organs throughout the body. In fact,
IL-33 has been detected in cells of both hematopoietic origin,
particularly in restricted populations of professional antigen
presenting cells such as macrophages and dendritic cells, and
in several different cell types of nonhematopoietic origin such
as fibroblasts, adipocytes, smooth muscle cells, endothelial
cells, bronchial and intestinal epithelial cells [8].
Initially, it was thought that IL-33 was synthesized as a
full-length 30 kD protein (full-length IL-33, f-IL-33) and pro-
cessed by caspase-1 upon inflammasome activation, resulting
in an alleged 18 kD bioactive peptide in a similar fashion to
the other major IL-1 family members, such as IL-1𝛽 and IL-
18 [8]. However, further investigation by three independent
research groups revealed that the inflammasome paradigm
for IL-33 did not occur in the in vivo setting and, instead,
demonstrated that f-IL-33 possessed full bioactivity, while
proapoptotic caspase-3 and -7 processed f-IL-33 into less
bioactive forms of 20–22 kD (cleaved IL-33, c-IL-33) [10–
12]. More recently, f-IL-33 has been shown to serve as a
substrate for neutrophil elastase and cathepsin G, resulting
in 18–22 kD peptides with an increased bioactivity of tenfold,
suggesting a possible extracellular mechanism to amplify
the effects of IL-33 during inflammatory conditions [13]. To
add further complexity to this scenario, an alternative splice
variant of IL-33 (spIL-33) has been described that is 5 kD
smaller than f-IL-33 and lacks the exons cleavable by caspases,
but possesses similar bioactivity to f-IL-33 [14]. Figure 1
summarizes the current knowledge regarding the different
IL-33 isoforms/splice variants and their bioactivity.
As previously mentioned, IL-33 exerts its biological
effects through the binding of its receptor, ST2, also known
as IL-1 receptor-like 1 (IL1RL1), belonging to the Toll-IL-1
Receptor (TIR) superfamily [8]. ST2 exists in two different
splice variants, leading to the synthesis of proteins with oppo-
site biological functions: ST2L, a transmembrane receptor
that activates downstream signaling upon IL-33 recognition,
and sST2, a soluble molecule that likely serves as a decoy
receptor by binding IL-33 and decreasing its availability to
ST2L, the IL-33 signaling receptor [15]. Similar to other TIR
receptors, ST2L requires pairing to a coreceptor in order to
initiate the downstream cell signaling cascade. As such, the
IL-33 receptor complex consists of ST2L and the IL-1 receptor
accessory protein (IL1RAcP), a TIR member also involved in
IL-18 signaling [16]. ST2 and IL1RAcP interact through their
TIR domain with MyD88, TRAF6, and IRAK1/4, eventually
leading to the activation of transcription factors, such as NF-
𝜅B and AP-1, which promote the production of several proin-
flammatory mediators [8]. Another IL-1 family coreceptor
member, that is, “single Ig IL-1R-related molecule” (SIGIRR)
or Tir8, can also dimerize with ST2 and likely acts as a nega-
tive regulator of the IL-33/ST2 signaling pathway, ultimately
reducing IL-33’s biological effects [17]. To date, a very limited
amount of information is available regarding the biologic and
pathophysiologic relevance of IL-33 isoforms/splice variants,
ST2 splice variants, and alternative ST2/SIGIRR signaling.
3. IL-33 Is a Key Player in Mucosal Immunity
against Intestinal Parasites
Since its first description, IL-33 has been reported to be
localized in barrier epithelia within organs/tissues in direct
contact with the external environment, including the skin,
airway, and gut epithelia, suggesting a possible role of
this cytokine in early immune responses against invasive
pathogens [8]. Moreover, several studies consistently show
that normal mice injected with recombinant IL-33 develop
a marked epithelial cell hyperplasia in the pulmonary and
GI tracts, together with an eosinophilic and mononuclear
infiltration into the lamina propria, specifically localized
in these barrier organs/tissues [18, 19]. Interestingly, the
production of a thick mucus layer is one effective mechanism
aimed to enhance epithelial barrier function and infers
protection of these mucosal organs. It is commonly thought
that these specific effects on intestinal epithelial cells are
mediated by the Th2 cytokine IL-13 [20, 21], which is abun-
dantly overexpressed after IL-33 stimulation/administration
[8]; however, the possibility that IL-33 per se promotes
epithelial differentiation towards a secretory type it may
not be ruled out. In fact, IL-33 is also a potent inducer of
Th2 cytokines that are pivotal in mounting potent immune
responses against helminthes and fungi; in fact, early papers
exploring IL-33 function have pointed out its fundamental
role in eliminating intestinal parasites. For example, Trichuris
muris, a nematode capable of infesting the GI tract, induces
the production of high levels of IL-33 from the infected
ceca of experimental animals [18]. In this experimental
setting, the administration of IL-33 was shown to boost
parasite clearance from host mice. Even though a significant
increase of NK cells was detected in mesenteric lymph
nodes (MLNs) from SCID and wild-type animals treated
with IL-33, parasite clearance appeared to be mediated
through T- and B-cell activation, as SCID mice failed to
eliminate T. muris upon IL-33 administration [18]. IL-33
appeared to have similar protective functions, enhancing
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Figure 1: IL-33 isoforms and their associated bioactivity. IL-33 is synthesized as a 30 kD protein (full-length-IL-33, f-IL-33); however,
alternative splicing can generate a 25 kD peptide (splice-IL-33, spIL-33), which possesses similar bioactivity to f-IL-33, but lacks caspase
cleavage sites.During cellular apoptosis, f-IL-33 serves as a potential substrate for pro-apoptotic caspases (caspase-3 and caspase-7), generating
smaller peptides of 20–22 kD with a marked reduction in bioactivity. Conversely, when secreted extracellularly, the proinflammatory activity
of f-IL-33 may be potentiated in the context of a permissive, proinflammatory environment. In fact, Cathepsin G and elastase, released
extracellularly by degranulating neutrophils, are able to cleave f-IL-33 into smaller isoforms (mature-IL-33, m-IL-33, 18–22 kD), which have
been reported to display the greatest bioactivity.
host responses against other parasitic and bacterial threats,
such as Toxoplasma gondii [22], Pseudomonas aeruginosa
[23], and Leptospira [24] infections, in different organ sys-
tems.
More recently, a growing body of evidence has shown
that IL-33’s protective effects against parasites are also medi-
ated by a newly identified innate immune cell population,
uniquely coined “nuocytes,” named after “nu,” the 13th letter
of the Greek alphabet, making reference to their ability
to produce high levels of IL-13 [19]. In fact, these innate
effector leukocytes display unique phenotypic characteristics
and are not aligned with any other known mature leuko-
cyte population. They express ICOS, CD45, ST2, and IL-
17BR and respond to IL-33 and/or IL-25 stimulation with
a significant increase in IL-13 expression [19]. In addition,
the transcription factor, ROR𝛼, has been described to be
necessary for their development [25]. Nuocytes appear to
be early initiators of Th2 responses, and their activation
is pivotal in eliciting worm clearance after Nippostrongylus
brasiliensis infection, but a Th2 response is not required for
nuocyte activity, as their development occurs inTh2 cytokine
deficient mice and in RAG2 knockout mice [19, 26]. At
the same time, similar IL-33/IL-25-responsive innate effector
cell populations have been described by others. Moro et
al. characterized a population, namely, natural helper cells
(NHC), identified by the presence of cell surface ST2, c-
Kit, Sca-1, and IL-7R, that reside in mesenteric adipose
tissue and are organized in fat-associated lymphoid clusters
[27]. Price et al. identified similar cells, but not expressing
either Sca-1 or c-Kit, which were coined innate helper 2
(Ih2) cells and that are widely distributed in mouse MLN,
spleen, liver, and bone marrow [28]. Together, these novel
cell populations and others (e.g., multipotent progenitor type
2 (MPPtype 2) cells [29]) are termed innate lymphoid cells
(ILCs) and share significant biologic similarities. As such, it
may be hypothesized that ILCs represent differentmaturation
steps or different differentiation phenotypes from the same
hematopoietic lineage. Nonetheless, nuocytes, NHC, and Ih2
cells are induced by IL-33 and are pivotal in mounting
effective immune responses against helminthes characterized
4 Mediators of Inflammation
by the overproduction of IL-5 and IL-13 and the induction
of histopathologic changes in the gut mucosa, including
epithelial/goblet cell hyperplasia and eosinophilic infiltration.
Whether or not these novel innate cell populations are the
only responsible for the induction of these pathologic features
is still debatable, as it has been clearly shown that IL-33
induces the production of chemokines for eosinophils [30]
and may also directly affect epithelial cell biology. It seems
reasonable that during parasitic infestation, in order to induce
a prompt innate response, cells constituting intestinal barrier,
such as epithelial cells and macrophages/dendritic cells, act
as a major source of IL-33/IL-25; however, at present, no
experimental data are available to confirm this hypothesis;
novel experimental tools may provide important insights
to this topic; in fact, mice genetically engineered to have
the𝛽-galactosidase-neomycin resistance fusion gene inserted
in IL-33 intron 1, the IL-33-LacZ gene trap reporter mice,
were recently described and used to specifically measure and
localize IL-33 promoter activity within mouse body; indeed,
these animals may be a valuable tool to identify the cellular
sources of IL-33 during health and disease conditions, such as
parasitic infestations. As a growing body of evidence confirms
the importance of IL-33-induced ILCs in the protection
against parasites, to date, the potential role of these novel cells
in spontaneous inflammatory conditions has not been fully
characterized in models of intestinal inflammation.
4. IL-33 and ST2 Are Dysregulated in IBD
IL-1 familymembers, coordinating early innate responses and
later adaptive immune responses, have been shown to play
an important role in the pathogenesis of chronic intestinal
inflammation, characterizing IBD [31, 32]. As such, IL-33
appeared to be a promising candidate to be studied in the set-
ting of human IBD. In fact, in 2010, four independent groups
described the dysregulation of IL-33 expression in patients
with UC and to a lesser extent, CD [33–36]. Consistently,
all groups showed increased protein levels of IL-33 within
the inflamed mucosa of IBD patients compared to healthy
controls, particularly in UC [33–36]. Immunohistochemistry
experiments revealed intense IL-33 staining in lamina propria
inflammatory infiltrates, primarily localizing in cells that
morphologically resemble macrophages and B cells/plasma
cells [35]. Importantly, nonhematopoietic cell types also
contribute to the augmented production of IL-33 during
intestinal inflammation; in particular, intestinal epithelial
cells [33, 35, 36] and myofibroblasts [34] display the highest
levels of IL-33 during active IBD. IL-33 was also detected
in other cell types within gut mucosa, confirming previous
reports in other organ systems, with expression in fibroblasts,
smooth muscle cells, endothelial cells [8, 37], and adipocytes
[38]. IL-33was also detectable in the sera of IBDpatients, with
concentrations significantly increased compared to healthy
controls [33, 35]. Circulating IL-33 levels were also found to
be markedly reduced upon anti-TNF administration (Inflix-
imab/Remicade) and may have the potential to be used as
a marker of disease activity and/or response to anti-TNF
treatment [35]. Intriguingly, IL-33 isoforms vary according to
the site wherein they are detected. In fact, f-IL-33 was the only
form found to be present in both the cytoplasm and nuclei
of IL-33-producing cells, such as intestinal epithelial cells,
whereas evaluation ofmucosal biopsies revealed the presence
of both f-IL-33 and 20–22 kD cleaved forms; conversely, sera
displayed exclusively the presence of the cleaved 20–22 kD
forms [35]. Taken together, these data suggest the presence
of extracellular proteases that have the ability to cleave IL-
33, possibly modulating its bioactivity. As mentioned earlier,
neutrophil elastase and cathepsin G are capable of cleaving f-
IL-33, generatingmore potent forms [13]. As such, the inflam-
matory milieu characterizing IBD may have the potential to
amplify IL-33’s biological effects. On the other hand, similar
to proapoptotic caspases, extracellular proteases may instead
have the ability to inactivate f-IL-33, perhaps in an attempt
to prevent possible harmful effects that may be triggered
by high circulating levels of this cytokine. Indeed, further
data are needed in order to clarify the significance of the
circulating forms of IL-33 and the mechanism(s) leading to
their generation.
Data regarding the analysis of IL-33 expression in human
IBDwere closely recapitulated in SAMP1/YitFc (SAMP)mice
[35], a spontaneousmodel of chronic intestinal inflammation
immunologically characterized by an early Th1 response and
a later mixedTh1/Th2 phenotype [39], both significantly con-
tributing to the extent of disease severity in these mice [40,
41]. In this study, SAMPmice were shown to display high IL-
33 levels in the serum as well as the gut mucosa, consistently
localized to intestinal epithelial cells andmacrophages within
the lamina propria. Interestingly, mucosal expression of IL-33
was found to positively correlate with the severity of SAMP
enteritis [35].
A substantial alteration of ST2 expression as well was
detected in the intestinal mucosa and sera from IBD patients.
ST2was abundantly expressed in the inflamedmucosa of IBD
patients compared to healthy controls, and similarly, elevated
circulating levels of sST2 were shown in UC and CD patients
[33, 35], correlating with mucosal ST2 expression and both
clinical and endoscopic disease activities [42]. Indeed, this
interesting piece of data may suggest that serum IL-33/sST2
is produced within intestinal mucosa and directly reflects
the severity of mucosal inflammation; as such, it would be
worthwhile to investigate the role of circulating IL-33 and
sST2 asmarkers of disease. Besides quantitative differences of
ST2 expression, striking qualitative alterations were detected
in the inflamed IBD mucosa versus healthy tissues. ST2 was
constitutively expressed by intestinal epithelial cells during
normal conditions; however, in chronically inflamed IBD
mucosa, intestinal epithelial cells lose ST2 expression, which
is redistributed to other inflammatory cell types. Specifically,
intestinal epithelial cells of UC patients did not present ST2,
whereas ST2 localized to lamina propria professional antigen
presenting cells and T helper lymphocytes [35]. If a robust
increase of ST2-positive cells within the lamina propria
infiltrate is a common feature of different inflammatory
conditions of the gut, the epithelial reduction/disappearance
of ST2 appears to be specific for IBD. In fact, in nonspecific
colitides, such as infectious colitis and diverticulitis, ST2
appears to be upregulated in both the epithelial and immune
Mediators of Inflammation 5
compartments of gut mucosa [35]. Of note, epithelial dysreg-
ulation of ST2 refers to a marked decrease of ST2L, the IL-33
transmembrane receptor, but not of the sST2 protein [33, 35].
As such, this particular pattern of expressionmay suggest that
during IBD, a severe impairment of IL-33 signalingwithin the
epithelial layer occurs, whereas IL-33/ST2 engagement may
be enhanced in intestinal immune cells. However, whether
this alteration of epithelial ST2L is a feedback response to
the chronic exposure of elevated IL-33 concentrations or an
intrinsic epithelial defect characterizing IBD has yet to be
determined.
Of note, during active IBD, an intense ST2 signal is
detectable in perivisceral adipose tissue, where a rich infil-
trate of ST2-positive immune cells is evident [35]. Consis-
tent with recent data in the literature, this particular ST2-
expressing cell population, dispersed within mesenteric fat,
may represent the NHC population, recently described by
Moro et al. [27], that are pivotal for the onset of immune
responses against parasites, but whose possible role in idio-
pathic intestinal inflammation has not yet been explored.
Remarkably, as a further confirmation of the dysregula-
tion of IL-33 and ST2 in human IBD, recent data, obtained in
an Italian cohort of adult and pediatric UC and CD patients,
demonstrate that specific IL-33 and ST2 gene polymorphisms
confer an increased risk of developing IBD (both UC and
CD), suggesting the involvement of the IL-33/ST2 axis in the
onset of chronic intestinal inflammation [43].
5. The IL-33/ST2 Axis Exerts
Dichotomous Functions during Idiopathic
Intestinal Inflammation
Despite robust data describing the changes in patterns of the
expression of IL-33 and ST2, current data regarding the role
of this novel cytokine/receptor pair in the onset of IBD is
conflicting and scarce. In fact, while some studies suggest a
proinflammatory function, others indicate a protective, anti-
inflammatory role.
Since its first description as a cytokine, IL-33 has been
shown to possess potent proinflammatory activity, inducing
Th2 cytokine production and promoting Th2 immunity.
Thus, IL-33 was initially identified as a possible target for
dampening inflammation in several animalmodels of inflam-
matory diseases, such as airway inflammation and arthritis
(i.e., ovalbumin challenge-induced airways inflammation
and collagen-induced arthritis) [44–46] since it was well
established that IL-33 had the ability to promote inflamma-
tion through both the recruitment [47] and activation [48]
of immune cells to the site of inflammation, as demonstrated
by data obtained in a Th2 cell adoptive transfer model
and in vitro. Consequently, mice overexpressing IL-33 were
reported to display spontaneous airway and lung inflam-
mation [49], whereas blocking the IL-33/ST2 axis decreased
inflammation in an experimental murine model of asthma
[44]. Similarly, antagonizing IL-33’s biological effects, using
anti-ST2 blocking antibodies, was effective in ameliorating
joint inflammation in amurinemodel of rheumatoid arthritis
[46]; in fact, the administration of IL-33 to cultures of
immune cells isolated from murine inflamed joints led to a
dramatic increase in IL-5, IL-6, and IL-17 production [45,
46]. These trends were also observed in a chronic model
of intestinal inflammation [35]. Unfractionated MLN cells,
collected from inflamed SAMP mice, secrete high levels of
the aforementioned cytokines when cultured in the presence
of IL-33 [35]. Of note, both IL-5 and IL-6 have been shown to
play a pathogenic role in SAMP ileitis, as demonstrated by
the amelioration of intestinal disease following either anti-
IL-5 or anti-IL-6 treatment [50, 51], whereas IL-17 has been
extensively characterized as a key cytokine inmany immune-
mediated diseases, including IBD [52–54]. Along these same
lines, unpublished data generated in our laboratory showed
that blockade of the IL-33/ST2 axis significantly reduces
intestinal inflammation in SAMP mice [55–57]. Mechanis-
tically, this effect appeared to be associated with a decrease
of lamina propria eosinophil infiltration, by downregulating
IL-5 and eotaxin-1 and eotaxin-2 [57], and by reducing
the percentages of IL-17 producing macrophages [55], a
population that has previously been described in intestinal
and airway inflammatory conditions [58, 59]. However, a full
phenotypic and functional characterization of this nonclassi-
cal cell population has not yet been performed. In addition,
IL-33-induced inflammation may play a role in the develop-
ment of intestinal fibrosis, as SAMP mice treated with anti-
ST2 blocking antibodies show decreased collagen deposition
within the intestinal wall, together with a reduced production
of pro-fibrotic molecules, such as transforming growth factor
(TGF)-𝛽, connective tissue growth factor (CTGF), collagen-1,
insulin growth factor (IGF)-1, and matrix metalloproteinase
(MMP)-9 [56]. Consistently, healthy AKR mice treated for
one week with intraperitoneal injections of recombinant IL-
33 developed a marked thickening of muscularis layer of
the intestinal wall, which was accompanied by increased
expression of collagen-1, collagen-3, IGF-1, and CTGF [56].
These data, along with the observation that in vitro IL-33
stimulation of human subepithelial myofibroblasts (SEMF)
induces the expression of profibrogenic genes such as col1a1,
col3a1, ctgf, and tgfb1 [56], suggest that IL-33 may also play
an important role in promoting inflammation-associated gut
fibrosis, as reviewed by Lopetuso et al. [60].
Additional data, primarily obtained from chemically
induced models of intestinal inflammation, provide further
insight into the role of IL-33 and ST2 in gut inflammatory
conditions. Oboki et al. induced colitis in IL-33 knockout
(KO) mice and wild-type littermates using dextran sodium
sulfate (DSS) administration [61]. The colonic inflammation
caused by DSS is primarily initiated by disruption of the
epithelial barrier, which results in bacterial translocation into
the underlying lamina propria. In this model, the resulting
inflammation is mediated by the activation of innate immune
responses and occurs in a T-cell-independent manner [62].
During the acute phase of this experimental model, IL-33
KO mice presented with reduced histologic inflammatory
scores, with a significant reduction of granulocyte infiltration
when compared to wild-type mice [61]. Other independent
groups replicated similar results, using the same acute animal
model [63–65]; in addition, Sedhom et al. confirmed the
pathogenic role of IL-33 also in a different model of intestinal
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inflammation, the trinitrobenzene-sulfonic-acid- (TNBS-)
induced colitis, which is obtained throughout the chemical
haptenization of protein expressed within the gut wall [64].
Interestingly, Sedhom et al. demonstrated on both DSS- and
TNBS-induced colitis that, during the onset of intestinal
inflammation, the IL-33/ST2 axis activation was able to affect
the non-haematopoietic component of the inflammatory
response, resulting in a significant impairment of the epithe-
lial barrier function [64]. Conversely, results obtained by
Oboki et al., during the recovery phase of the DSS-induced
colitis in IL-33 KO mice, suggest that IL-33 might have
different roles during different phases of the inflammatory
process; in fact, weight recovery was markedly delayed in
IL-33 KO mice, with a slight increase in mortality rate [61].
These results suggest that IL-33 is a critical amplifier of innate
immune responses within the gut mucosa, whereas its role
in the maintenance of chronic inflammation is less clear.
Alternatively, IL-33 may possess an important functional role
in enhancing innate immune responses related to bacterial
clearance or in promoting mucosal wound healing.
Despite its well-known proinflammatory properties, IL-
33 has also shown protective functions in different diseases;
in fact, early reports demonstrated that IL-33 exerts a cardio-
protective effect, reducing overload-induced cardiomyocyte
hypertrophy [66]; on the same line, Miller et al. showed that
IL-33 reduced the development of atherosclerosis [37] and the
inflammation within the adipose tissue of obese mice [67],
confirming the beneficial effect of IL-33 on the cardiovascular
system. In addition, IL-33 appeared to have some protective
role on various inflammatory conditions as well. For example,
IL-33 appears to reduce inflammation in Con-A hepatitis
[68], in central nervous system demyelinating disorders [69],
and in pancreatitis [70]. Moreover, the ability of IL-33 to
recruit neutrophils to the site of inflammation has been
shown to reduce the consequences of severe septic events [71],
whereas the IL-33-mediated expansion of IL-4-producing
basophils, upon high-dose immunoglobulin administration,
has been shown to induce profound immunoregulatory
effects [72]. The dichotomous nature of IL-33 has also
led to the generation of conflicting data in the setting of
intestinal inflammation. In fact, data generated on the spon-
taneous enteritis characterizing SAMP mice suggests a frank
pathogenic role, while IL-33 KOmice undergoing DSS colitis
develop a mixed response. In addition, chronic DSS colitis
appears to be less severe after IL-33 administration [73]. In
these studies, Gro𝛽 et al. induced both acute and chronic DSS
colitis in balb/c mice and administered IL-33 to experimental
animals using different protocols. When IL-33 was injected
during the first cycle of DSS, colonic inflammation was more
severe, with a dramatic increase in neutrophil infiltration;
conversely, treating animals during the recovery phases of
both acute and chronic DSS colitis decreased inflammatory
scores and improved epithelial regeneration [73]. A different
group reported partially overlapping results using a similar
acute DSS protocol. Utilizing the acute DSS colitis model,
Imaeda et al. administered IL-33 every 48 hours. In these
studies, the authors reported increased inflammatory scores
in IL-33-treated balb/c mice; however, when evaluating the
epithelial layer, complete reversion of the goblet cell depletion
characteristic of DSS colitis was observed [63]. This effect
appeared to be mediated by the suppression of Notch ligand
expression by SEMFs. In fact, the Notch pathway is a key
regulator of epithelial cell differentiation, leading towards an
absorptive phenotype [74]. As such, IL-33-mediated inhi-
bition of the Notch pathway resulted in the maturation of
epithelial cells towards a goblet cell phenotype, likely rep-
resenting a protective response against harmful conditions
[63]. Interestingly and along similar lines, IL-33 expression
has been reported in SEMFs underlying ulcerated epithelia
in UC and gastric ulcers [34, 75]. In addition, recent data
suggest that IL-33 stimulation may increase gastric epithelial
proliferation [76], whereas dramatic changes in the pattern of
IL-33 expression in endothelial cells have been described dur-
ing angiogenesis [77]. Overall, these data together strongly
suggest that the IL-33/ST2 axis may be implicated in the
maintenance of intestinal barrier function, wherein pertur-
bations may likely play an important role in the development
of chronic inflammatory conditions of the gut. As such, we
can speculate that IL-33 may enhance bacterial clearance by
inducing early granulocyte infiltration, promoting epithelial
differentiation towards a mucus-secreting phenotype, and by
facilitating wound healing. The redistribution/loss of ST2L
within the epithelial compartment described during UC [33,
35] is consistent with the goblet cell depletion characterizing
this particular disease and can also account for a defective
wound healing process that can contribute to the chronicity
of the inflammatory process.
Data generated byDuan et al. using theTh1-drivenTNBS-
induced colitis, opposing to what was shown by Sedhom et
al., suggested more immune-mediated/immunomodulatory
properties of IL-33 [78]. Using this model, mice developed
less severe colitis following intraperitoneal injections of IL-33,
whereas anti-IL-33 antibody administration did not signifi-
cantly affect intestinal inflammation. The anti-inflammatory
effects of IL-33 appeared to be mediated by a decreased
production of the prototypic Th1 cytokine, IFN𝛾, while the
Th2 cytokines, IL-5 and IL-13, were found to be increased.
The authors conclude that IL-33 has the ability to initiate
Th1 to Th2 skewing. In addition, the authors also infer that
IL-33 has the ability to promote tolerogenic dendritic cell
development, which ultimately results in the expansion of the
T regulatory cell population [78]. Thus, during Th1-driven
inflammation, IL-33 may have the capability to modulate gut
mucosal immune responses to a moreTh2-driven phenotype
and promote the expansion of regulatory cell types. The
different functions of the IL-33/ST2 axis during intestinal
inflammation in SAMP spontaneous enteritis and in the
chemically induced DSS- and TNBS-induced colitis models
are recapitulated in Figure 2.
6. IL-33 As an Alarmin: A Possible
Unifying Solution
Indeed, the IL-33/ST2 axis appears to be widely represented
throughout the whole body, having different, and sometimes
opposing, functions. The resulting balance between the
differential effects appears to be straightforward in certain



































Figure 2: Role of IL-33 in murine models of intestinal inflammation. Experimental results obtained from SAMP mice that develop
spontaneousTh1/Th2-driven enteritis suggest a pathogenic role for IL-33 at the onset of intestinal inflammation in this specific model. In fact,
epithelial-derived IL-33 promotes the release of proinflammatory cytokines from LP immune cells, enhancing both Th1 and Th2 responses.
Moreover, IL-33 induces the production of eotaxin-1 and eotaxin-2, which leads to eosinophil chemotaxis to the inflamed gut. In addition,
IL-33 activates the expression of profibrotic genes, contributing to the development of intestinal fibrosis (upper panel). Different results
are observed in chemically induced models of intestinal inflammation (middle and lower panels). During the onset of acute DSS-induced
colitis, IL-33, likely released by necrotic/damaged epithelial cells, participates in the development of intestinal inflammation with a potent
chemotactic effect on neutrophils, cells that play a pivotal role in this specific model of colitis (middle panel). Conversely, during the recovery
phase of chronic DSS colitis, IL-33 appears to promote wound healing, inducing the restoration of epithelial barrier integrity. On the contrary,
when IL-33 is administered to mice displaying a TNBS-induced colitis, which is mainly driven by a Th1 immune response, IL-33 shows an
anti-inflammatory effect as a result of the skewing towards aTh2 immunophenotype and the potential induction of T regulatory cell activation
(lower panel).
tissue/organ systems, such as the airways/lungs or the joints,
where inflammation, in itself, is the major detrimental agent
to cause pathology. In more complex systems, wherein
mucosal immune responses interact with a large bacterial
load and epithelial barrier integrity and function is essential
to consider, such as that found in chronic intestinal inflam-
mation, the final outcome of this intricate interplay is difficult
to predict and may vary according to slightly modifications
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of the initial conditions. In fact, IL-33 appears to enhance
intestinal inflammation in disease models, which are driven
by Th2 and innate immune responses, such that observed
in SAMP mice and the acute phase of DSS colitis, and
possibly in UC patients. Conversely, IL-33’s effects during
a Th1-driven model, such as in TNBS colitis, may result
in decreased intestinal inflammation mediated by cytokine
and cell-mediated modulation of immune responses. On
the other hand, emerging evidence suggests that IL-33 may
have positive effects on epithelial repair and barrier function.
High levels of IL-33 during acute inflammation are likely
to worsen tissue damage, whereas they may enhance tissue
repair during recovery, promoting wound healing and the
restoration of the epithelial barrier, as shown in the DSS
model. Thus, the initial features of the specific immune
response and the timing of IL-33 administration/blockade
may dictate the overall outcome of disease pathogene-
sis.
The nuclear localization sequence in IL-33’s primary
structure suggested a possible role and function for this
cytokine as an “alarmin,” that is, a protein released from
dying/suffering cells as an extracellular sign of danger [79].
Consistent with this hypothesis is the fact that IL-33 is
released by cells undergoing mechanical stress [80] and is
cleaved by pro-apoptotic caspases into less active forms [10–
12]. Moreover, data obtained on mononuclear cells confirm
that IL-33 is overexpressed after TLR-2 and -4 stimulation,
but it is released only when necrosis of these cells is induced
[81]. On the same line, it has been shown that other dan-
ger signals, such as extracellular ATP, different pathogen-
associated molecular patterns (PAMPs), and inflammasome
activation, lead to the increased production of IL-33 in
different cell types (i.e., glial cells, airway epithelial cells) [82–
84]. Indeed, the “alarmin” paradigm may have the potential
to reconcile how IL-33 possesses such a wide spectrum of
effects in the gastrointestinal tract. That is, upon harmful
stimuli, IL-33 is released by suffering epithelial barrier cells in
order to recruit and activate immune cells and clear potential
pathogens. At the same time, the presence of a defective and
damaged epithelial barrier must be quickly repaired, and the
need for prompt epithelial restitution and wound healing is
promoted.
Interestingly, IBD genetic studies have identified a few
candidate susceptibility genes, encoding proteins that are piv-
otal for themaintenance of epithelial cell integrity, such as the
endoplasmic reticulum stress protein, proteins related to the
autophagy process, and structural proteins [1]. It is tempting
to speculate that when epithelial function is severely impaired
as a consequence of mutations of the aforementioned genes,
suffering intestinal epithelial cells may release high levels of
IL-33, activating a potentially detrimental immune response.
At the same time, the loss/dysregulation of ST2L on intestinal
epithelial cells in IBD may alter epithelial restoration. As
such, further, more mechanistic investigation is warranted
to dissect this complicated scenario, aiming to clarify the
specific effects of the IL-33/ST2 axis, at different times as
well as the contribution of different cellular sources, in order
to elucidate the predominant role of this complex cytokine
system in the pathogenesis of intestinal inflammation.
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